Outcomes of isolated limb perfusion in the treatment of extremity soft tissue sarcoma: a systematic review.

[1]  A. Morais.  Is it worthwhile? , 2013, Revista portuguesa de pneumologia.

[2]  J. Verweij,et al.  Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. , 2012, The Lancet. Oncology.

[3]  A. Eggermont,et al.  Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Ross,et al.  Isolated limb perfusion for unresectable extremity sarcoma , 2011, Cancer.

[5]  E. Bastiaannet,et al.  TNF dose reduction and shortening of duration of isolated limb perfusion for locally advanced soft tissue sarcoma of the extremities is safe and effective in terms of long‐term patient outcome , 2011, Journal of surgical oncology.

[6]  A. Eggermont,et al.  Radiotherapy for Soft Tissue Sarcomas after Isolated Limb Perfusion and Surgical Resection: Essential for Local Control in All Patients? , 2010, Annals of Surgical Oncology.

[7]  I. Judson,et al.  Guidelines for the management of soft tissue sarcomas . The British Sarcoma Group , 2010 .

[8]  L. de la Cruz-Merino,et al.  Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. , 2010, The oncologist.

[9]  P. Terrier,et al.  Hyperthermic Isolated Limb Perfusion in Locally Advanced Soft Tissue Sarcoma and Progressive Desmoid-Type Fibromatosis with TNF 1 mg and Melphalan (T1-M HILP) Is Safe and Efficient , 2009, Annals of Surgical Oncology.

[10]  O. Merimsky,et al.  Efficacy of high vs low dose TNF-isolated limb perfusion for locally advanced soft tissue sarcoma. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  K. Schmid,et al.  Evaluation of 47 Soft Tissue Sarcoma Resection Specimens after Isolated Limb Perfusion with TNF-α and Melphalan: Histologically Characterized Improved Margins Correlate with Absence of Recurrences , 2009, Annals of Surgical Oncology.

[12]  R. Mirimanoff,et al.  Isolated limb perfusion with tumor necrosis factor and melphalan for non‐resectable soft tissue sarcomas: Long‐term results on efficacy and limb salvage in a selected group of patients , 2008, Journal of surgical oncology.

[13]  H. Hoekstra,et al.  Isolated Limb Perfusion and External Beam Radiotherapy for Soft Tissue Sarcomas of the Extremity: Long-Term Effects on Normal Tissue According to the LENT-SOMA Scoring System , 2008, Annals of Surgical Oncology.

[14]  S. Devesa,et al.  Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases , 2006, International journal of cancer.

[15]  B. Bui,et al.  Prospective evaluation of quality of surgery in soft tissue sarcoma. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[16]  H. Hoekstra,et al.  Quality of Life After Hyperthermic Isolated Limb Perfusion for Locally Advanced Extremity Soft Tissue Sarcoma , 2006, Annals of Surgical Oncology.

[17]  J. Blay,et al.  Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-α be better? , 2005 .

[18]  S. Mocellin,et al.  Hyperthermic Isolated Perfusion with Low-Dose TNFα and Doxorubicin in Patients with Locally Advanced Soft Tissue Limb Sarcomas , 2004, Journal of chemotherapy.

[19]  A. Eggermont,et al.  Regional treatment of metastasis: role of regional perfusion. State of the art isolated limb perfusion for limb salvage. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  F. van Coevorden,et al.  Isolated limb perfusion with tumor necrosis factor‐α and melphalan for patients with unresectable soft tissue sarcoma of the extremities , 2003, Cancer.

[21]  A. Eggermont,et al.  Current uses of isolated limb perfusion in the clinic and a model system for new strategies. , 2003, The Lancet. Oncology.

[22]  M. Lens,et al.  Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials. , 2003, The Lancet. Oncology.

[23]  A. Eggermont.  Isolated limb perfusion in the management of locally advanced extremity soft tissue sarcoma. , 2003, Surgical oncology clinics of North America.

[24]  R. Grimer,et al.  Should Soft Tissue Sarcomas be Treated at a Specialist Centre? , 2003, Sarcoma.

[25]  R. Harbour,et al.  A new system for grading recommendations in evidence based guidelines , 2001, BMJ : British Medical Journal.

[26]  H. Akgül,et al.  Isolated limb perfusion with cisplatin and doxorubicin for locally advanced soft tissue sarcoma of an extremity. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[27]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[28]  M. Inbar,et al.  High dose tumor necrosis factor‐α and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation , 1997, Cancer.

[29]  P. Schlag,et al.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. , 1996, Annals of surgery.

[30]  V. Ninfo,et al.  Phase II study on neoadjuvant hyperthermic‐antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas , 1994, Cancer.

[31]  H. S. Moseley,et al.  An evaluation of two methods of limb salvage in extremity soft-tissue sarcomas. , 1992, Archives of surgery.

[32]  S. Carlini,et al.  Hyperthermic antiblastic perfusion for the treatment of soft tissue limb sarcoma. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  A. Rydholm,et al.  Is local recurrence of minor importance for metastases in soft tissue sarcoma? , 1991, Cancer.

[34]  C. Fisher,et al.  The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival , 1990, Cancer.

[35]  E. V. van Slooten,et al.  Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. , 1982, European journal of cancer & clinical oncology.

[36]  R. F. Ryan,et al.  Chemotherapy of Cancer: Regional Perfusion Utilizing an Extracorporeal Circuit , 1958, Annals of surgery.

[37]  C. Beauchamp.  Advanced Extremity Soft Tissue Sarcoma: Prognostic Effect of Isolated Limb Perfusion in a Series of 88 Patients Treated at a Single Institution , 2008 .

[38]  J. Thomas,et al.  Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. , 2007, Annals of surgical oncology.

[39]  E. Glatstein.  Isolated Limb Perfusion With Tumor Necrosis Factor α and Melphalan for Locally Advanced Soft Tissue Sarcoma: The Value of Adjuvant Radiotherapy , 2007 .

[40]  A. Eggermont,et al.  The palliative value of tumor necrosis factor α‐based isolated limb perfusion in patients with metastatic sarcoma and melanoma , 2006, Cancer.

[41]  J. Blay,et al.  Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  P. Visca,et al.  Liposomal doxorubicin in the perfusional treatment of advanced soft tissue limb sarcoma. , 2004, Journal of chemotherapy.

[43]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[44]  W. Molenaar,et al.  Hyperthermic isolated limb perfusion with tumour necrosis factor α and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile? , 1998, Archives of Orthopaedic and Trauma Surgery.

[45]  N. Renard,et al.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.